Influence of the proto-oncogene c-fos on cisplatin sensitivity

Biochemical Pharmacology

Volumn 59, Issue 4, 2000, Pages 337-345

  Moorehead, Roger A ^a   Singh, Gurmit ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Antisense oligonucleotides; c fos; Cisplatin; Combination chemotherapy; Ovarian carcinoma; Resistance

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; MESSENGER RNA; PROTEIN C FOS;

ANIMAL CELL; ARTICLE; CELL LINE; DRUG RESISTANCE; DRUG SENSITIVITY; FIBROBLAST CULTURE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL SURVIVAL; CISPLATIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLASTS; GENE EXPRESSION; GENES, FOS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; TUMOR CELLS, CULTURED;

EID: 0033981899     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00333-0     Document Type: Article

References (27)

1. Perez R.P., Hamilton T.C., Ozols R.F. Resistance to alkylating agents and cisplatin Insights from ovarian carcinoma model systems. Pharmacol Ther. 48:1990;19-27.
2. Scanlon K.J., Kashani-Sabet M., Miyachi H., Sowers L.C., Rossi J. Molecular basis of cisplatin resistance in human carcinomas Model systems and patients. Anticancer Res. 9:1989;1301-1312.
3. Andrews P.A. Mechanisms of acquired resistance to cisplatin. Ozols R.F., Goldstein L.J. Cancer Treatment and Research. 1994;217-248 Kluwer Academic, Boston.
4. Scanlon K.J., Jiao L., Funato T., Wang W., Tone T., Rossi J.J., Kashani-Sabet M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA. 88:1991;10591-10595.
5. Kashani-Sabet M., Wang W., Scanlon K.J. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem. 265:1990;11285-11288.
6. Scanlon K.J., Wang W., Han H. Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. Cancer Treat Rev. 17:(Suppl A):1990;27-35.
7. Chiu R., Boyle W.J., Meek J., Smeal T., Hunter T., Karin M. The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell. 54:1988;541-552.
8. Schuermann M. The Fos family Gene and protein structure, homologies, and differences. Angel P.E., Herrlich P.A. The FOS and JUN Families of Transcription Factors. 1994;15-35 CRC Press, Boca Raton.
9. Kovary K., Bravo R. The Jun and Fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol. 11:1991;4466-4472.
10. 1 transition and during exponential growth in mouse fibroblasts Differential role of Fos proteins. Mol Cell Biol. 12:1992;5015-5023.
11. Hollander M.C., Fornace A.J. Jr. Induction of fos RNA by DNA-damaging agents. Cancer Res. 49:1989;1687-1692.
12. Amstad P.A., Krupitza G., Cerutti P.A. Mechanism of c-fos induction by active oxygen. Cancer Res. 52:1992;3952-3960.
13. Kaina B., Haas S., Kappes H. A general role for c-Fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. Cancer Res. 57:1997;2721-2731.
14. Arteaga C.L., Holt J.T. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res. 56:1996;1098-1103.
15. Roth J.A., Cristiano R.J. Gene therapy for cancer What have we done and where are we going? J Natl Cancer Inst. 88:1997;21-39.
16. Miao G.G., Curran T. Cell transformation by c-fos requires an extended period of expression and is independent of cell cycle. Mol Cell Biol. 14:1994;4295-4310.
17. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal Biochem. 150:1985;76-85.
18. Moorehead R.A., Singh G. Sensitisation of cisplatin-resistant cells using dequalinium chloride. Cell Pharmacol. 2:1995;311-317.
19. Moorehead R.A., Armstrong S.G., Wilson B.C., Singh G. Cross-resistance to cisplatin in cells resistant to photofrin-mediated photodynamic therapy. Cancer Res. 54:1994;2556-2559.
20. Rideout D.C., Chou T.-C. Synergism, antagonism, and potentiation in chemotherapy An overview. Chou T.-C., Rideout D.C. Synergism and Antagonism in Chemotherapy. 1991;3-60 Academic Press, San Diego.
21. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
22. Maxam A.M., Gilbert W. Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol. 65:1980;499-560.
23. Andrews P.A., Albright K.D. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res. 52:1992;1895-1901.
24. Zinkewich-Péotti K., Andrews P.A. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res. 52:1992;1902-1906.
25. Jiao L., Funato T., Wang W., Tone T., Kashani-Sabet M., Scanlon K.J. The role of the c-fos oncogene in cisplatin resistance. Howell S.B. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. 1991;303-313 Plenum Press, New York.
26. Zhen W., Link C.J. Jr, O'Connor P.M., Reed E., Parker R., Howell S.B., Bohr V.A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol. 12:1992;3689-3698.
27. Miller A.D., Curran T., Verma I.M. c-fos Protein can induce cellular transformation A novel mechanism of activation of a cellular oncogene. Cell. 36:1984;51-60.